Avidity Partners Management’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-258,000
Closed -$40.4M 86
2022
Q4
$40.4M Buy
+258,000
New +$37.1M 0.87% 37
2021
Q1
Sell
-792,100
Closed -$94.4M 106
2020
Q4
$94.4M Buy
792,100
+390,100
+97% +$47.6M 3.06% 7
2020
Q3
$46M Buy
+402,000
New +$47.5M 2.13% 16

Other funds holding DGX

Avidity Partners Management's DGX Position: Q1 2023 in Review

Avidity Partners Management sold out of Quest Diagnostics (DGX) in Q1 2023, closing a stake of 258,000 shares — an estimated $40.4M sold.

Avidity Partners Management first reported a position in DGX in Q3 2020 and held it in 3 quarters. The position peaked at $94.4M in Q4 2020. 834 funds tracked by Wall St. Rank hold DGX as of Q1 2023.

  • Avidity Partners Management reported no remaining Quest Diagnostics position as of Q1 2023 after selling out during the quarter.
  • Avidity Partners Management sold 258,000 Quest Diagnostics shares in Q1 2023, an estimated $40.4M.
  • Avidity Partners Management first reported a position in Quest Diagnostics in Q3 2020 and held it in 3 quarters.
  • Avidity Partners Management's Quest Diagnostics position peaked at $94.4M in Q4 2020.
  • 834 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2023.

Based on Avidity Partners Management's 13F filing for Q1 2023, filed 15 May 2023.